The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447248 | PMC |
| http://dx.doi.org/10.1136/ejhpharm-2020-002322 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the association between pro-inflammatory mediators and sarcopenia in cancer patients through different diagnostic tools: a narrative review.
Ann Transl Med
December 2024
Post-Graduation Department, Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, Brazil.
Background And Objective: Sarcopenia, characterized by the progressive loss of skeletal muscle mass (MM) and muscle function, is a common and debilitating condition in cancer patients, significantly impacting their quality of life, treatment outcomes, and overall survival. The pathophysiology of sarcopenia is multifactorial, involving metabolic, hormonal, and inflammatory changes. Recent research highlights the role of chronic inflammation in the development and progression of sarcopenia, with pro-inflammatory cytokines being key mediators of muscle catabolism.
View Article and Find Full Text PDFInterleukin-17A facilitates tumor progression upregulating programmed death ligand-1 expression in hepatocellular carcinoma.
World J Gastrointest Oncol
January 2025
The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, Gansu Province, China.
Background: Hepatocellular carcinoma (HCC) is an inflammation-associated tumor with a dismal prognosis. Immunotherapy has become an important treatment strategy for HCC, as immunity is closely related to inflammation in the tumor microenvironment. Inflammation regulates the expression of programmed death ligand-1 (PD-L1) in the immunosuppressive tumor microenvironment and affects immunotherapy efficacy.
View Article and Find Full Text PDFIntegrating Network Pharmacology and In Silico Analysis to Explore the Bioactive Compounds Against Gastric Cancer Treatment.
Cureus
December 2024
Community Medicine, Siksha 'O' Anusandhan Deemed to be University Institute of Medical Sciences and SUM Hospital, Bhubaneswar, IND.
Gastric cancer (GC) has become a major challenge in oncology research, primarily due to its detection at advanced stages. In this study, we identified and validated the pharmacological mechanisms involved in treating gastric cancer using an integrated approach combining network pharmacology, molecular docking, and a dynamic approach. Gastric cancer-related genes were obtained from DisGeNET, Genecard, and Malacard databases, while potential targets of bioactive compounds were predicted using SwissTargetPrediction.
View Article and Find Full Text PDFComparative Analysis of Biochemical and Lipid Profile Markers at Different Stages of Lung Cancer: A Cross-Sectional Study.
Cureus
December 2024
Biochemistry, Meenakshi Medical College Hospital and Research Institute, Meenakshi Academy of Higher Education and Research, Kanchipuram, IND.
Background: Systemic inflammation, metabolic dysregulation, and changes in biochemical markers are closely associated with the progression of lung cancer. This study focuses on evaluating serum parathyroid hormone (PTH), C-reactive protein (CRP), lipid profile parameters, and interleukin-6 (IL-6) in relation to the stages of lung cancer, exploring their potential as biomarkers for assessing disease severity.
Methods: A total of 160 lung cancer patients were selected for a cross-sectional study and equally distributed into four clinical stages (Stages 1-4).
Association between vitamin D levels with IL-6 and IL-10 in umbilical cord blood of infants.
Narra J
December 2024
Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.
A worldwide issue, vitamin D deficiency affects pregnant mothers and babies everywhere, including Indonesia. It involves the adaptive immune system by controlling the production of pro-and anti-inflammatory cytokines and the balance between humoral (Th2) and cell-mediated (Th1) immunity. The aim of this study was to investigate the relationship between vitamin D and the cytokines IL-6 and IL-10 in infants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!